Paul S. Charifson

5.7k total citations · 1 hit paper
55 papers, 4.0k citations indexed

About

Paul S. Charifson is a scholar working on Molecular Biology, Computational Theory and Mathematics and Organic Chemistry. According to data from OpenAlex, Paul S. Charifson has authored 55 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Molecular Biology, 11 papers in Computational Theory and Mathematics and 10 papers in Organic Chemistry. Recurrent topics in Paul S. Charifson's work include Protein Structure and Dynamics (11 papers), Cancer therapeutics and mechanisms (11 papers) and Computational Drug Discovery Methods (11 papers). Paul S. Charifson is often cited by papers focused on Protein Structure and Dynamics (11 papers), Cancer therapeutics and mechanisms (11 papers) and Computational Drug Discovery Methods (11 papers). Paul S. Charifson collaborates with scholars based in United States, France and Germany. Paul S. Charifson's co-authors include W. Patrick Walters, Emanuele Perola, Mark A. Murcko, David A. Pearlman, Lee G. Pedersen, Yunyi Wei, Christian H. Gross, Jonathan D. Parsons, Lora Swenson and Steven D. Wyrick and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Biochemistry.

In The Last Decade

Paul S. Charifson

53 papers receiving 3.9k citations

Hit Papers

Consensus Scoring:  A Met... 1999 2026 2008 2017 1999 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Consensus Scoring:  A Method for Obtaining Improved Hit Rates from Docking Databases of Three-Dimensional Structures into Proteins
    1999 517 citations Paul S. Charifson, Mark A. Murcko et al. Journal of Medicinal Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul S. Charifson United States 29 2.9k 1.3k 726 463 362 55 4.0k
Robert C. Rizzo United States 30 2.7k 1.0× 1.3k 0.9× 695 1.0× 566 1.2× 355 1.0× 63 4.6k
Nadine Homeyer Germany 11 3.3k 1.2× 1.1k 0.8× 671 0.9× 487 1.1× 501 1.4× 18 4.9k
G. Madhavi Sastry India 16 3.1k 1.1× 1.6k 1.2× 1.1k 1.5× 380 0.8× 550 1.5× 27 5.3k
Claudio N. Cavasotto United States 37 2.7k 0.9× 1.8k 1.3× 576 0.8× 431 0.9× 275 0.8× 85 4.2k
A. Geoffrey Skillman United States 17 2.5k 0.9× 1.9k 1.4× 693 1.0× 614 1.3× 244 0.7× 26 3.8k
Maria A. Miteva France 37 3.2k 1.1× 2.0k 1.5× 728 1.0× 442 1.0× 550 1.5× 129 5.2k
Steven L. Dixon United States 27 2.3k 0.8× 2.1k 1.5× 972 1.3× 470 1.0× 320 0.9× 46 4.2k
Shuanghong Huo United States 21 4.0k 1.4× 1.1k 0.8× 611 0.8× 712 1.5× 488 1.3× 42 5.5k
Catherine E. Peishoff United States 16 2.1k 0.7× 1.6k 1.2× 608 0.8× 365 0.8× 240 0.7× 30 3.3k
Michal Vieth United States 25 2.4k 0.8× 1.4k 1.1× 727 1.0× 439 0.9× 444 1.2× 41 3.7k

Countries citing papers authored by Paul S. Charifson

Since Specialization
Citations

This map shows the geographic impact of Paul S. Charifson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul S. Charifson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul S. Charifson more than expected).

Fields of papers citing papers by Paul S. Charifson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul S. Charifson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul S. Charifson. The network helps show where Paul S. Charifson may publish in the future.

Co-authorship network of co-authors of Paul S. Charifson

This figure shows the co-authorship network connecting the top 25 collaborators of Paul S. Charifson. A scholar is included among the top collaborators of Paul S. Charifson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul S. Charifson. Paul S. Charifson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Das, Krishna Mohan, Jun Chen, Paul S. Charifson, et al.. (2025). Inhibition of dimeric SARS-CoV-2 Mpro displays positive cooperativity and a mixture of covalent and non-covalent binding. iScience. 28(7). 112773–112773.
2.
Hillier, Shawn, David Newsome, Daigo Takemoto, et al.. (2016). Preclinical characterization of the selective DNA-dependent protein kinase (DNA-PK) inhibitor VX-984 in combination with chemotherapy. Annals of Oncology. 27. vi122–vi122. 4 indexed citations
3.
Boyd, Michael J., Upul K. Bandarage, Wenxin Gu, et al.. (2015). Isosteric replacements of the carboxylic acid of drug candidate VX-787: Effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 25(9). 1990–1994. 26 indexed citations
4.
Byrn, Randal A., Steven J.M. Jones, Michael P. Clark, et al.. (2014). Preclinical Activity of VX-787, a First-in-Class, Orally Bioavailable Inhibitor of the Influenza Virus Polymerase PB2 Subunit. Antimicrobial Agents and Chemotherapy. 59(3). 1569–1582. 149 indexed citations
5.
Gu, Wenxin, Tiansheng Wang, François Maltais, et al.. (2012). Design, synthesis and biological evaluation of potent NAD+-dependent DNA ligase inhibitors as potential antibacterial agents. Part I: Aminoalkoxypyrimidine carboxamides. Bioorganic & Medicinal Chemistry Letters. 22(11). 3693–3698. 12 indexed citations
6.
Wang, Tiansheng, Wenxin Gu, Hardwin O’Dowd, et al.. (2012). Design, synthesis and biological evaluation of potent NAD+-dependent DNA ligase inhibitors as potential antibacterial agents. Part 2: 4-Amino-pyrido[2,3-d]pyrimidin-5(8H)-ones. Bioorganic & Medicinal Chemistry Letters. 22(11). 3699–3703. 13 indexed citations
7.
Badia, Michael C., S.F. Bellon, Anne‐Laure Grillot, et al.. (2010). Discovery of pyrazolthiazoles as novel and potent inhibitors of bacterial gyrase. Bioorganic & Medicinal Chemistry Letters. 20(9). 2828–2831. 85 indexed citations
8.
Pearlman, David A., B. Govinda Rao, & Paul S. Charifson. (2008). FURSMASA: A new approach to rapid scoring functions that uses a MD‐averaged potential energy grid and a solvent‐accessible surface area term with parameters GA fit to experimental data. Proteins Structure Function and Bioinformatics. 71(3). 1519–1538. 7 indexed citations
9.
Charifson, Paul S. & W. Patrick Walters. (2002). Filtering databases and chemical libraries. Journal of Computer-Aided Molecular Design. 16(5-6). 311–323. 44 indexed citations
10.
Wei, Yunyi, Ted Fox, Joyce T. Coll, et al.. (2000). The structures of caspases-1, -3, -7 and -8 reveal the basis for substrate and inhibitor selectivity. Chemistry & Biology. 7(6). 423–432. 166 indexed citations
11.
Charifson, Paul S.. (1997). Practical Application of Computer-Aided Drug Design. 136 indexed citations
12.
Brown, Peter J., Tracey Smith-Oliver, Paul S. Charifson, et al.. (1997). Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library. Chemistry & Biology. 4(12). 909–918. 86 indexed citations
13.
Mehrotra, Mukund M., Daniel D. Sternbach, Marc Rodriguez, Paul S. Charifson, & Judd Berman. (1996). α-Dicarbonyls as “non-charged” arginine-directed affinity labels. Novel synthetic routes to α-dicarbonyl analogs of the PP60c-src SH2 domain-targeted phosphopeptide Ac-Tyr(OPO3H2)-Glu-Glu-Ile-Glu. Bioorganic & Medicinal Chemistry Letters. 6(16). 1941–1946. 5 indexed citations
14.
Willson, Timothy M., Brad R. Henke, Paul S. Charifson, et al.. (1994). 3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats. Journal of Medicinal Chemistry. 37(11). 1550–1552. 115 indexed citations
15.
Charifson, Paul S., Nora S. Kula, Andrew T. McPhail, et al.. (1994). Conformational Analysis, Pharmacophore Identification, and Comparative Molecular Field Analysis of Ligands for the Neuromodulatory .sigma.3 Receptor. Journal of Medicinal Chemistry. 37(24). 4109–4117. 42 indexed citations
16.
Frech, Matthias, Tom Darden, Lee G. Pedersen, et al.. (1994). Role of Glutamine-61 in the Hydrolysis of GTP by p21H-ras: An Experimental and Theoretical Study. Biochemistry. 33(11). 3237–3244. 112 indexed citations
17.
Bowen, J. Phillip, Paul S. Charifson, Maria Kontoyianni, et al.. (1993). Computer‐Assisted Molecular Modeling: Indispensable Tools for Molecular Pharmacology. The Journal of Clinical Pharmacology. 33(12). 1149–1164. 8 indexed citations
18.
Foley, C. K., Lee G. Pedersen, Paul S. Charifson, et al.. (1992). Simulation of the solution structure of the H-ras p21-GTP complex. Biochemistry. 31(21). 4951–4959. 38 indexed citations
19.
Charifson, Paul S., J. Phillip Bowen, Steven D. Wyrick, et al.. (1989). Conformational analysis and molecular modeling of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as D1 dopamine receptor ligands. Journal of Medicinal Chemistry. 32(9). 2050–2058. 41 indexed citations
20.
Charifson, Paul S., Steven D. Wyrick, Andrew J. Hoffman, et al.. (1988). Synthesis and pharmacological characterization of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as dopamine receptor ligands. Journal of Medicinal Chemistry. 31(10). 1941–1946. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert C. Rizzo Breakdown of academic impact, for papers by Nadine Homeyer Breakdown of academic impact, for papers by G. Madhavi Sastry Breakdown of academic impact, for papers by Claudio N. Cavasotto Breakdown of academic impact, for papers by A. Geoffrey Skillman Breakdown of academic impact, for papers by Maria A. Miteva Breakdown of academic impact, for papers by Steven L. Dixon Breakdown of academic impact, for papers by Shuanghong Huo Breakdown of academic impact, for papers by Catherine E. Peishoff Breakdown of academic impact, for papers by Michal Vieth
Rankless by CCL
2026